* WHO sees some 'decoupling' of COVID-19 cases and deaths
* Raising global vaccine rates will reduce Omicron's impact
* Calls for global coordination on vaccine development
(Adds quotes, bullets, context throughout)
By Emma Farge and Mrinalika Roy
GENEVA, Jan 4 (Reuters) - More evidence is emerging that the
Omicron coronavirus variant is affecting the upper respiratory
tract, causing milder symptoms than previous variants and
resulting in a "decoupling" in some places between soaring case
numbers and low death rates, a World Health Organization
official said on Tuesday.
"We are seeing more and more studies pointing out that
Omicron is infecting the upper part of the body. Unlike other
ones, the lungs who would be causing severe pneumonia," WHO
Incident Manager Abdi Mahamud told Geneva-based journalists.
"It can be a good news, but we really require more studies
to prove that."
Since the heavily mutated variant was first detected in
November, WHO data shows it has spread quickly and emerged in at
least 128 countries, presenting dilemmas for many nations and
people seeking to reboot their economies and lives after nearly
two years of COVID-related disruptions.
However, while case numbers have surged to all-time records,
the hospitalisation and death rates are often lower than at
other phases in the pandemic.
"What we are seeing now is....the decoupling between the
cases and the deaths," he said.
His remarks on the reduced risks of severe disease chime
with other data, including a study from South Africa https://www.reuters.com/world/africa/safrica-study-suggests-lower-risk-hospitalisation-with-omicron-versus-delta-2021-12-22,
which was one of the first countries where Omicron was
detected.
However, Mahamud also sounded a note of caution, calling
South Africa an "outlier" since it has a young population, among
other factors.
And he warned that Omicron's high transmissibility meant it
would become dominant within weeks in many places, posing a
threat to medical systems in countries where a high proportion
of the population remains unvaccinated.
VACCINATION, NOT VACCINES, ARE THE CHALLENGE
While Omicron seemed to be slipping past antibodies,
evidence was emerging that COVID-19 vaccines still provided some
protection, by eliciting a second pillar of the immune response
from T-cells, Mahamud said.
"Our prediction is protection against severe hospitalization
and death (from Omicron) will be maintained," he said, saying
this also applied to vaccines developed by Sinopharm and Sinovac
that are used in China, where Omicron cases remain very low.
"The challenge has not been the vaccine but the vaccination
and reaching those vulnerable populations."
Asked about whether an Omicron-specific vaccine was needed,
Mahamud said it was too early to say but voiced doubts and
stressed that the decision required global coordination and
should not be left to manufacturers to decide alone.
"You may go ahead with Omicron and put all your eggs in that
basket and a new variant that is more transmissible or more
immune-evasive may appear," he said, adding that a WHO technical
group had held recent meetings on vaccine composition.
The best way to reduce the impact of the variant would be to
meet the WHO's goal of vaccinating 70% of the population in each
country by July, rather than offer third and fourth doses in
some countries, he said.
As case numbers due to Omicron have soared, some countries,
including the United States https://www.reuters.com/world/us/cdc-cuts-quarantine-time-all-americans-with-covid-19-5-days-2021-12-27,
have cut down isolation or quarantine periods in a bid to allow
asymptomatic people to return to work or school.
Mahamud said that leaders should decide based on the
strength of the local epidemic, saying Western countries with
very high case numbers might consider trimming isolation periods
to keep basic services functioning.
However, places that have largely shut it out would do
better to maintain the full 14-day quarantine period.
"If your numbers are very small, you better be invested in
keeping that number very, very low."
(Reporting by Emma Farge and Mrinalika Roy in Bangalore;
Editing by Andrew Cawthorne and Alex Richardson)
((emma.farge@thomsonreuters.com;))